Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study

IMPORTANCE: Atezolizumab (anti–programmed cell death ligand 1 [PD-L1]) is well tolerated and clinically active in multiple cancer types. Its safety and clinical activity in metastatic triple-negative breast cancer (mTNBC) has not been reported. OBJECTIVE: To evaluate the safety, clinical activity, a...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:JAMA Oncol
Main Authors: Emens, Leisha A., Cruz, Cristina, Eder, Joseph Paul, Braiteh, Fadi, Chung, Cathie, Tolaney, Sara M., Kuter, Irene, Nanda, Rita, Cassier, Philippe A., Delord, Jean-Pierre, Gordon, Michael S., ElGabry, Ehab, Chang, Ching-Wei, Sarkar, Indrani, Grossman, William, O’Hear, Carol, Fassò, Marcella, Molinero, Luciana, Schmid, Peter
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2018
Teme:
Original Investigation
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6439773/
https://ncbi.nlm.nih.gov/pubmed/30242306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.4224
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki